Oncology PracticeTLR9 agonist may overcome resistance to anti–PD-1 therapy in melanomaNovember 12, 2019MelanomaImmunotherapyImmuno-oncology
Oncology PracticeMelanoma incidence continues to increase, yet mortality stabilizingNovember 7, 2019Melanoma
Oncology PracticeCase-control study IDs several novel risk factors of post-HCT melanomaNovember 6, 2019MelanomaPatient & Survivor CareTransplantation
Oncology PracticeLevothyroxine dose for checkpoint inhibitor toxicity may be too highNovember 4, 2019MelanomaLung CancerPatient & Survivor CareImmunotherapy
Oncology PracticeNivolumab-ipilimumab nets long-term survival in advanced melanomaOctober 5, 2019MelanomaImmuno-oncology
Oncology PracticeCancer burden: Multiple metrics needed to clarify the big pictureOctober 4, 2019Breast CancerGastroenterologyMelanomaGenitourinary CancerRenal Cell CarcinomaGastrointestinal Cancer
Oncology PracticePrior antibiotic use lowers checkpoint inhibitor response and survivalSeptember 12, 2019Immuno-oncologyLung CancerPatient & Survivor CareMelanoma
Oncology PracticeDabrafenib plus trametinib yields long-term benefit in melanoma patientsAugust 14, 2019Melanoma
Oncology PracticeStudy outlines survival factors with nivolumabJuly 25, 2019Lung CancerRenal Cell CarcinomaMelanomaImmuno-oncology
Oncology PracticeCases of pediatric invasive melanoma have declined since 2002, study findsJuly 22, 2019PediatricsMelanoma
Oncology PracticeIL-6, CRP are prognostic for checkpoint inhibition in melanomaJuly 19, 2019MelanomaImmuno-oncology
